Host: |
Goat |
Applications: |
Pep-ELISA/WB/IHC |
Reactivity: |
Human/Mouse/Rat/Dog/Cow |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Goat polyclonal antibody anti-PEBP1 (C-Term) is suitable for use in ELISA, Western Blot and Immunohistochemistry research applications. |
Clonality: |
Polyclonal |
Conjugation: |
Unconjugated |
Isotype: |
IgG |
Formulation: |
0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin. NA |
Purification: |
Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide. |
Concentration: |
0.5 mg/mL |
Dilution Range: |
WB-Recommended for use at 0.5-2µg/mlIHC-5µg/mlELISA-antibody detection limit dilution 1:32000. |
Storage Instruction: |
Store at-20°C on receipt and minimise freeze-thaw cycles. |
Gene Symbol: |
PEBP1 |
Gene ID: |
5037 |
Uniprot ID: |
PEBP1_HUMAN |
Immunogen Region: |
C-Term |
Accession Number: |
NP_002558.1 |
Immunogen Sequence: |
DYVPKLYEQLSGK |
Protein Name | Phosphatidylethanolamine-Binding Protein 1Pebp-1HcnpppNeuropolypeptide H3Prostatic-Binding ProteinRaf Kinase Inhibitor ProteinRkip Cleaved Into - Hippocampal Cholinergic Neurostimulating PeptideHcnp |
Database Links | Reactome: R-HSA-5674135Reactome: R-HSA-5675221Reactome: R-HSA-6802946Reactome: R-HSA-6802948Reactome: R-HSA-6802952Reactome: R-HSA-6802955Reactome: R-HSA-9649948 |
Cellular Localisation | Cytoplasm |
Alternative Antibody Names | Anti-Phosphatidylethanolamine-Binding Protein 1 antibodyAnti-Pebp-1 antibodyAnti-Hcnppp antibodyAnti-Neuropolypeptide H3 antibodyAnti-Prostatic-Binding Protein antibodyAnti-Raf Kinase Inhibitor Protein antibodyAnti-Rkip Cleaved Into - Hippocampal Cholinergic Neurostimulating Peptide antibodyAnti-Hcnp antibodyAnti-PEBP1 antibodyAnti-PBP antibodyAnti-PEBP antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance